PMID: 9429236Jan 16, 1998Paper

Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations

Pharmacogenetics
H G XieH H Zhou

Abstract

Data on both the incidence of slow acetylator phenotype of probe drugs isoniazid, sulfadimidine or sulfamethazine, caffeine and dapsone in mainland or overseas Chinese, and the distribution of NAT2 genotypes and the frequency of NAT2 alleles in the Chinese populations were summarized and reanalysed using a meta-analysis method. Frequency of the slow acetylator phenotype in 3516 healthy Han Chinese gave an overall mean of approximately 19.9 +/- 4.0%, with the range of the combined data being between 15.8% and 25.5%. In addition, frequencies of the slow acetylator phenotype differ between the different minorities in Chinese populations and the range was between 3.2% and 50.6%, with a mean value of 20.6 +/- 12.9% in a total of 1842 individuals from 17 Chinese minorities. In addition, there was no significant heterogeneity in overseas Chinese between the probe drugs isoniazid and sulfadimidine or sulfamethazine (chi 2 = 5.97, df = 4; p > 0.05), and the mean value of slow acetylator phenotype incidence was 24.5% (119/485; 95% CI: 20.7-28.3%), consistent with that of the native Chinese. As expected, frequency of the slow acetylator genotypes in Chinese populations was 25.4% (112/441; 95% CI: 21.3-29.5%), which was in accordance with ...Continue Reading

Citations

Mar 30, 2006·European Journal of Clinical Pharmacology·Bing ChenWei-Min Cai
Jun 14, 2006·European Journal of Clinical Pharmacology·Nicolas VuilleumierDenis Hochstrasser
Jan 5, 2002·Obstetrics and Gynecology·L B SignorelloS Cnattingius
Jun 29, 2002·Cancer Detection and Prevention·Alexandre LoktionovJohn H Cummings
Sep 19, 2009·Pharmacogenomics·Raúl J AndradeM Isabel Lucena
Dec 20, 2007·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·Rikke EgebergAnne Tjønneland
Jun 5, 2008·Expert Opinion on Drug Metabolism & Toxicology·Marissa J ScandlynRhonda J Rosengren
Mar 1, 2011·Alcoholism, Clinical and Experimental Research·Kai-Chung YangShou-Dong Lee
May 13, 2015·Journal of Comparative Effectiveness Research·Kyle R Fluegge, Brian E Roe
Mar 19, 2014·Journal of Toxicology and Environmental Health. Part B, Critical Reviews·Hassan R Dhaini, Loulou Kobeissi
Feb 1, 2005·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Rama D MittalAnil Mandhani
Sep 12, 2002·Clinical Pharmacokinetics·Zeruesenay DestaDavid A Flockhart
Sep 14, 2006·Pharmacological Reviews·Sharon J Gardiner, Evan J Begg
Oct 6, 1999·British Journal of Clinical Pharmacology·H G XieA J Wood
Nov 8, 2014·Asia-Pacific Journal of Clinical Oncology·Md Bayejid HosenYearul Kabir
Jun 23, 2020·Indian Journal of Dermatology·Daya Shankar Lal SrivastavaGajendra Singh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.